Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Stoke Therapeutics Inc shares valued at $51,158 were sold by Ticho Barry on Aug 18 ’25. At $18.24 per share, Ticho Barry sold 2,805 shares. The insider’s holdings dropped to 23,970 shares worth approximately $0.46 million following the completion of this transaction.
Also, Kaye Edward M. MD sold 12,126 shares, netting a total of over 221,154 in proceeds. Following the sale of shares at $18.24 each, the insider now holds 153,470 shares.
Before that, Allan Jonathan had sold 1,683 shares from its account. In a trade valued at $30,695, the GENERAL COUNSEL & CORP SEC traded Stoke Therapeutics Inc shares for $18.24 each. Upon closing the transaction, the insider’s holdings decreased to 1,683 shares, worth approximately $0.46 million.
As published in their initiating research note from Jefferies on July 18, 2025, Stoke Therapeutics Inc [STOK] has been a Buy and the price target has been revised to $30. Analysts at Chardan Capital Markets started covering the stock with ‘”a Buy”‘ outlook in a report released in mid December. Earlier on March 26, 2024, TD Cowen upgraded its rating. Their new recommendation was “an Outperform” for STOK stock which previously was a “a Market perform”.
Analyzing STOK Stock Performance
On last trading session, Stoke Therapeutics Inc [NASDAQ: STOK] rose 4.49% to $19.32. The stock’s lowest price that day was $18.06, but it reached a high of $19.48 in the same session. During the last five days, there has been a surge of approximately 14.25%. Over the course of the year, Stoke Therapeutics Inc shares have jumped approximately 32.06%. Shares of the company reached a 52-week high of $19.48 on 08/20/25 and a 52-week low of $5.35 on 04/09/25.
Support And Resistance Levels for Stoke Therapeutics Inc (STOK)
According to the 24-hour chart, there is a support level at 18.43, which, if violated, would cause prices to drop to 17.53. In the upper region, resistance lies at 19.85. The next price resistance is at 20.37. RSI (Relative Strength Index) is 85.71 on the 14-day chart, showing overbought technical sentiment.
Is Stoke Therapeutics Inc subject to short interest?
Stocks of Stoke Therapeutics Inc saw a sharp steep in short interest on 2025-07-31 dropping by -0.1 million shares to 11.43 million. Data from Yahoo Finance shows that the short interest on 2025-06-30 was 11.53 million shares. A decline of -0.91% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 15.4 of the overall float, the days-to-cover ratio (short ratio) decline to 15.4.
Which companies own the most shares of Stoke Therapeutics Inc (STOK)?
In terms of Stoke Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 28 in the next 12 months, up nearly 51.43% from the previous closing price of $18.49. Analysts anticipate Stoke Therapeutics Inc stock to reach 28 by 2025, with the lowest price target being 28. In spite of this, 5 analysts ranked Stoke Therapeutics Inc stock as Buy at the end of 2025.
